Navidea Biopharmaceuticals To Collaborate With University of Alabama at Birmingham On Clinical Study Evaluating The RIGS&#0153 Monoclonal Antibody Targeting Agent

Published: Nov 26, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will collaborate with investigators at the University of Alabama at Birmingham (UAB) on a clinical study to evaluate the safety and activity of a radiolabeled, humanized monoclonal antibody (Mab) from its RIGSā„¢ Monoclonal Antibody Targeting technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news